

1 Table, Supplemental Digital Content 1.

2 **Author biographies and experience relating to management of digoxin toxicity**

| Author                       | Experience  |
|------------------------------|---|
| Paul Andrews, BM             | After training at Southampton Medical School, Dr Andrews undertook a variety of posts in general internal medicine and was appointed as a consultant physician in 2012. He has a postgraduate diploma in medical toxicology from Cardiff University and a Diploma in forensic medical sciences from the Society of Apothecaries. He has been a member of the European Association of Poisons Centres and Clinical Toxicologists and the American Academy of Clinical Toxicology since 2008.   |
| Kurt Anseeuw, MD, MSc        | Board certified emergency physician, with additional training in toxicology. Involved in clinical care of toxicology patients, and provides advice to healthcare professionals on diagnosis and management of toxicology cases, including digoxin toxicity, for over 20 years.  |
| Dipak Kotecha, MD, PhD, MSc  | Professor of Cardiology and Consultant Cardiologist, European Society of Cardiology guideline taskforces for atrial fibrillation, and lead/chief investigator for numerous clinical studies and trials, including contemporary use of digoxin therapy.  |
| Frédéric Lapostolle, MD, PhD | Active in research into and management of digoxin poisoning for over 20 years; publications including: <ul style="list-style-type: none"> <li>• Lapostolle F, Devallière E, Alhéritière A, Adnet F. Relation between creatinine level and kalaemia in patients with digitalis poisoning. <i>Presse Med.</i> 2012 Dec;41(12 Pt 1):1297-9</li> <li>• Pautas É, Lopez C, Gouronnec A, Gravelaine S, Peyron I, Lapostolle F. Focus on digitalis intoxication in the elderly. Report of a case treated with digoxin-specific Fab antibody fragments. <i>Geriatr Psychol Neuropsychiatr Vieil.</i> 2012 Dec;10(4):355-63</li> </ul> |

Digoxin toxicity management consensus: Manuscript

|                            |   |
|----------------------------|---|
|                            | <ul style="list-style-type: none"><li>• Maillaud C, Barguil Y, Mikulski M, Cheze M, Pivert C, Deveaux M, Lapostolle F. First successful curative use of digoxin-specific Fab antibody fragments in a life-threatening coconut crab (<i>Birgus latro</i> L.) poisoning. <i>Toxicol.</i> 2012 Nov;60(6):1013-7</li><li>• Lapostolle F, Borron SW, Verdier C, Taboulet P, Guerrier G, Adnet F, Clemessy JL, Bismuth C, Baud FJ. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. <i>Crit Care Med.</i> 2008 Nov;36(11):3014-8</li><li>• Lapostolle F, Borron SW, Verdier C, Arnaud F, Couvreur J, Mégarbane B, Baud F, Adnet F. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. <i>Intensive Care Med.</i> 2008 Aug;34(8):1448-53</li></ul> |
| Ruben Thanacoody, MD, FRCP | Consultant clinical toxicologist in the UK National Poisons Information Service, providing advice to healthcare professionals on management of cases of digoxin toxicity for over 20 years.   |

3

4